Clinical trials: Cancer Breast
Breast Cancer
Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00323063
- Testing
- gemcitabine hydrochloride, imatinib mesylate
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- Rutgers, The State University of New Jersey
Malignant Neoplasm of Breast, Breast Cancer
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
This study will test the theory that therapy designed for each individual's tumor will improve outcomes over standard of care in a population that needs a better standard.
- Trial name
- NCT02101385
- Testing
- Genomically Directed Monotherapy, Observation/Standard Therapy
- Where
- 29 sites in United States
- Volunteers
- 193 people
- Sponsor
- Bryan Schneider, MD
Breast Cancer
Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy
Primary Objective: To evaluate if low BRCA1 protein expression has a preferential effect on response when metastatic breast cancer patients are treated with DNA damaging chemotherapy agent, compared to historical controls…
- Trial name
- NCT01990352
- Testing
- Pegylated liposomal doxorubicin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Arizona
Colorectal Cancer, Squamous Cell Head and Neck Cancer
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
- Conditions
- Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT01451632
- Testing
- MM-121, Irinotecan, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Merrimack Pharmaceuticals
Breast Carcinoma
Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy
This phase III trial studies how well Mepitel Film works in reducing radiation dermatitis (redness and peeling) in patients with breast cancer during radiation therapy after a mastectomy.
- Trial name
- NCT04989504
- Testing
- Best Practice, Wound Dressing Material, Quality-of-Life Assessment
- Where
- 49 sites in United States
- Volunteers
- 216 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer Female
A Post-Market Clinical Trial to Evaluate the Performance and Operation of the Brevera Breast Biopsy System
The Brevera Breast Biopsy System integrates tissue acquisition, real time imaging, and post biopsy handling all during the same procedure.
- Trial name
- NCT03300206
- Testing
- Breast Biopsy
- Where
- 7 sites in United States
- Volunteers
- 525 people
- Sponsor
- Hologic, Inc.
Breast Cancer
The Breast Cancer Online Rehabilitation Program
The investigators have developed an online rehabilitation platform to guide women in their home-based upper-body exercises after breast cancer surgery.
- Trial name
- BRECOR (NCT02673918)
- Testing
- Home-based upper-body rehabilitation with online support
- Where
- 6 sites in Denmark
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Lung Cancer, Esophageal Cancer
Mithramycin for Lung, Esophagus, and Other Chest Cancers
Background: Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted against some forms of cancer, but was never accepted as a treatment.
- Conditions
- Lung Cancer, Esophageal Cancer, Mesothelioma, Gastrointestinal Neoplasms
- Trial name
- NCT01624090
- Testing
- Mithramycin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Breast Neoplasms
Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors
This objective of this randomized controlled trial is to conduct a 2x2 test of a lifestyle intervention and metformin (a drug used to treat diabetes) to investigate how these treatments, alone or in combination, affect biomarkers…
- Trial name
- NCT01302379
- Testing
- Metformin, Lifestyle intervention, Standard printed dietary guidelines
- Where
- United States
- Volunteers
- 333 people
- Sponsor
- University of California, San Diego
Breast Cancer, Hormonreceptor Positive
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
The PENELOPEB study is designed to demonstrate that, in the background of standard anti-hormonal therapy, palbociclib provides superior invasive disease-free survival (iDFS) compared to placebo in pre- and postmenopausal women…
- Conditions
- Breast Cancer, Hormonreceptor Positive, Her2-normal, Postneoadjuvant Treatment With CDK 4/6 Inhibitor
- Trial name
- PENELOPE-B (NCT01864746)
- Testing
- Palbociclib PD-0332991
- Where
- 11 sites in United States, Australia and 9 more
- Volunteers
- 1,250 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer
Evaluation of Accelerated Partial Breast Brachytherapy
Over the past two decades, breast conserving therapy (BCT) has become a major treatment modality for Stage I and II breast carcinoma.
- Trial name
- NCT00593346
- Testing
- brachytherapy
- Where
- United States
- Volunteers
- 151 people
- Sponsor
- Washington University School of Medicine
Breast Cancer, Radiation Dermatitis
MediHoney for Radiation Dermatitis
The aim of this study is to compare the effects of Medihoney and Hydrophor on radiation dermatitis reactions in a group of women undergoing radiation therapy for breast cancer.
- Trial name
- NCT02234479
- Testing
- Hydrophor (Group A), MediHoney (Group B)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Maryland, Baltimore
Invasive Breast Cancer
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
This study is being done to test the safety and effectiveness of two drugs, Anastrozole and Fulvestrant, used as combined therapy in the neo-adjuvant setting for hormone receptor positive invasive breast cancer.
- Trial name
- NCT00921115
- Testing
- Fulvestrant, Anastrazole
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Kansas Medical Center
Breast Cancer
Study of Dual-energy (DE) Contrast-enhanced (CE) Digital Mammography
This is a feasibility study to evaluate dual-energy (DE) contrast-enhanced (CE) digital mammography to detect breast cancer in patients with increased breast density (BI-RADS category c or d).
- Trial name
- NCT02995980
- Testing
- Dual-Energy Contrast-Enhanced (DECE) mammography, digital mammography
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
MGC018 With or Without MGA012 in Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult
- Trial name
- NCT03729596
- Testing
- vobramitamab duocarmazine
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 143 people
- Sponsor
- MacroGenics
Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen.
- Conditions
- Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- SOFT (NCT00066690)
- Testing
- Exemestane, Laboratory Biomarker Analysis, Oophorectomy
- Where
- 500 sites in United States, Canada and 1 more
- Volunteers
- 3,066 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer, Breast Carcinoma
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
The goal of this clinical research study is to learn if the study drug, alisertib (MLN8237), in combination with chemotherapy (paclitaxel), can shrink or slow tumor growth in women with hormone receptor (HR)-positive, human…
- Conditions
- Breast Cancer, Breast Carcinoma, Breast Tumors, Malignant Neoplasm of Breast
- Trial name
- NCT02187991
- Testing
- Paclitaxel, Alisertib
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- US Oncology Research
Ductal Carcinoma in Situ
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor
This will be a proof of principle clinical trial to evaluate the use of pasireotide (SOM230) in women with ductal carcinoma in situ (DCIS) of the breast.
- Trial name
- NCT01372618
- Testing
- SOM 230 / Pasireotide
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Lung Cancer, Tobacco Use Disorder
Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
RATIONALE: Continued smoking after a cancer diagnosis has important health consequences beyond the risks associated with smoking in the general population.
- Conditions
- Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer
- Trial name
- NCT01434342
- Testing
- Nicotine Replacement Patch
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Wake Forest University Health Sciences
Nausea
Nexium Study To Suppress Nausea During Chemotherapy
This study will look at a drug called esomeprazole, the newest PPI, as a way to further reduce the amount of nausea and vomiting seen in breast cancer patients receiving adriamycin or epirubicin chemotherapy.
- Trial name
- NEXIUM (NCT00206440)
- Testing
- esomeprazole
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Baylor Breast Care Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.